Health Care • Biotechnology: Pharmaceutical Preparations
$6.36 ▼ -0.22
(-3.34%)
MKT CAP: $12.3M • VOL: 76.3K
52W L $3 52W H $8
ROARABLE / RQD
E • 28/100
PIOTROSKI
2 / 9
BOLT // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $7.7M | $7.7M | $7.9M |
| YoY Revenue Growth % | +0.1% | -2.4% | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$36.1M | -$73.0M | -$76.2M |
| Operating Margin % | -80.0% | -80.0% | -80.0% |
| Net Income (GAAP) | -$33.4M | -$63.1M | -$69.2M |
| EBITDA (Normalized) | -$36.1M | -$73.0M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$39.9M | -$61.3M | -$69.5M |
| Capital Expenditures (CapEx) | $72.0K | $41.0K | — |
| Free Cash Flow (FCF) | -$39.9M | -$61.3M | -$69.5M |
| FCF Margin % | -80.0% | -80.0% | -80.0% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $11.7M | $7.2M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $26.5M | $57.2M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR BOLT.